Emergency loans for Swiss biotechs

This survey is closed - please do not enter data

To strengthen the Swiss biotech industry’s arguments and negotiation position towards the State Secretary for Economic Affairs (SECO), we would appreciate if you replied to this survey as soon as possible but no later than April 15.

We appreciate your support and hope that we can jointly secure that emergency loans (or an equivalent measure) will also become available for Swiss biotech companies in due course.

Please reply no later than April 20, 2020, midday

If you wish to participate anonymously in the survey, do not provide your name, e-mail address or company name.

This survey ONLY works on a desktop browser (no mobile usage possible, sorry)

To input multiple answers, press and hold “Ctrl”, and select the suiting answers by clicking with your mouse.

Full name

Did you plan to close a financing round? (multiple answers possible)

What is the total amount you intended to raise?

Do you still see a chance to close the round(s) as planned?

By when do you think the liquidity reserves of your company will be exhausted?

Do you have any comments related to your financing need and current situation?

Do you currently experience significant delays in running one or more of the following activities (multiple answers possible)

If you selected "other" as delayed activity, please outline

Expected delay for internal pre-clinical experiments

Expected delay for external collaborations with CROs

Expected delay for external collaborations with academic partners

Expected delay for clinical trials

Other expected delays, not including the above

Do you currently benefit from (multiple answers possible)

Do you benefit from cost reductions due to other measures (e.g. cantonal solutions) or negotiations?

Do you currently incur fixed costs that you cannot avoid for (multiple answers possible):

Do you have other fixed costs than the above you cannot avoid?

Do you experience (other than stated above) negative impacts due to the Covid-19 pandemic?

Do you require specific support from the Swiss Biotech Association? What topics should we address with the federal or local authorities?

If you develop a solution to address the Covid-19 pandemic are you...(multiple answers possible)

If you chose diagnostic as Covid-19 solution, please outline type of diagnostic

If you chose other as Covid-19 solution, please specify